Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs. apixaban in patients with atrial fibrillation despite ...

Stroke and systemic embolism occur at a low rate after catheter-based atrial ablation and may result in substantial sequelae or even death in certain cases.

A series of neutral trials on anticoagulation in embolic stroke of undetermined source (ESUS) has moved the needle scientifically but left physicians with questions about secondary prevention and the ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

We conducted an international, open-label, randomized, blinded-outcome-assessment trial involving 1284 patients who had undergone successful catheter ablation for atrial fibrillation at least 1 year ...

NEW YORK, NY—Use of a cerebral embolic protection device (EPD) during TAVI may prevent disabling strokes, but any effect appears to be modest, according to an updated analysis of the Society of ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Blood clots can turn dangerous quickly if ignored. This article highlights eight key warning signs—from swelling to ...

High blood pressure is the main modifiable risk factor for preventing cardiovascular events in people who have had a stroke or transient ischaemic attack; however, only approximately one in three ...